M&A Deal Summary

Geistlich Pharma North America Acquires Lynch Biologics

On October 27, 2022, Geistlich Pharma North America acquired life science company Lynch Biologics

Acquisition Highlights
  • This is Geistlich Pharma North America’s 1st transaction in the Life Science sector.
  • This is Geistlich Pharma North America’s 1st transaction in the United States.
  • This is Geistlich Pharma North America’s 1st transaction in Tennessee.

M&A Deal Summary
Date 2022-10-27
Target Lynch Biologics
Sector Life Science
Buyer(s) Geistlich Pharma North America
Deal Type Add-on Acquisition

Target

Lynch Biologics

Franklin, Tennessee, United States
Lynch Biologics is a regenerative medicine and tissue engineering company supplying advanced biotechnology products that promote healing and tissue regeneration spearheaded by GEM 21S®, and other widely used regenerative products, for periodontal and oral and maxillofacial indications. Lynch Biologics was founded in 2013 and is based in Franklin, Tennessee.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Geistlich Pharma North America

Princeton, New Jersey, United States
Category Company
Sector Life Science
DESCRIPTION

Geistlich Pharma North America is a provider of technological advances that make regenerative treatment, with safe and naturally sourced biomaterials, the preferred choice for clinical predictability. Geistlich Pharma North America is based in Princeton, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Tennessee) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Mergr

Product

Company

Legal